Quick Renal MRI for Pediatric Kidney Disease
Trial Summary
What is the purpose of this trial?
The investigators propose a new imaging method for children born with congenital anomalies of the urinary tract that is a rapid, injection-, sedation-, and radiation-free alternative: the quick renal MRI. This proposal hypothesizes that the quick renal MRI has high validity compared to current radiologic standard for renal infection and scarring, the 99mTechnetium-dimercaptosuccinic acid (99mTc- DMSA) renal scan in the detection of acute renal infections and scars. If the quick renal MRI is accurate, it could potentially replace the DMSA scan for those specific questions and ease the burden of testing for children with chronic renal disease. Findings from these studies will provide preliminary data and rationale for a multi-centered study to further test this new technology.Participants will be 0-21 years of age and can expect to be on study for from 1 week (if enrolled in Aim 1) to 6 months (if enrolled in Aim 2).
Research Team
Shannon Cannon, MD
Principal Investigator
University of Wisconsin, Madison
Eligibility Criteria
This trial is for children and young adults (0-21 years) with kidney conditions like infections or scarring, who are already getting DMSA scans as part of their care. It's not for those uncomfortable with MRI, without signs of infection in urine tests, negative urine cultures, or who can't have an MRI due to other medical reasons.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Aim 1: Acute Pyelonephritis Evaluation
Inpatients with acute pyelonephritis undergo a clinical DMSA scan and quick MRI within one week of each other.
Aim 2: Renal Scarring Evaluation
Patients with renal scarring undergo a clinical DMSA scan and quick MRI within 6 months of each other.
Follow-up
Participants are monitored for safety and effectiveness after imaging procedures.
Treatment Details
Interventions
- Quick MRI
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Wisconsin, Madison
Lead Sponsor